Arrowhead Pharmaceuticals, Inc.

NASDAQ:ARWR

Biotechnology

Healthcare
$43.11 +5.87%

+$4.49 today

Market cap
$6.09B
Beta
1.27
P/E (TTM)
-38.4
EPS (TTM)
-$2.11
52W Low $14.30High $82.48

Volume 2.42M

Average 1.82M

ARWR Pre-Tax Margin

Income before tax as a percentage of revenue.

Arrowhead Pharmaceuticals, Inc.NASDAQ: ARWR

Pre-Tax Margin · Q4 FY2026 · quarter ended Sep 2026

Pre-tax margin narrows to -1152.9%

Pre-tax margin was -1152.9% in Q4 FY2026, down 1166.9 pp from a year earlier. On a trailing-twelve-month basis it was -160.6%, down 166.8 pp year over year. Over 3 fiscal years it narrowed by 74.8 pp.

Context

  • Pre-tax margin widened in 1 of the last 3 fiscal years.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
-1152.9%-915.1 pp QoQ
Last fiscal yearSep 2026
-160.6%-166.8 pp YoY
LTMSep 2026
-160.6%-166.8 pp YoY
Pre-Tax Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-1166.9 pp——
1 year-166.8 pp——
3 years-74.8 pp——
5 years——
10 years——

Pre-Tax Margin history

Percent of revenue · from the income statement

Latest · FY2026
-160.6%
Year-over-year change
-166.8pp

Pre-Tax Margin vs competitors

How ARWR compares with its peers on the latest reported figures

  • ARWR's LTM Sep 2026 pre-tax margin of -160.6% is the 3rd highest of the 7 companies compared; the peer median is -214.6%.
  • Its year-over-year change of -166.8 pp is the 5th highest of 6, against a peer median of -122.7 pp.
  • Over three fiscal years its change of -74.8 pp compares with a peer median of +60.5 pp.
ARWR Competitors Peer median
Pre-Tax Margin for ARWR and competitors
Company Period LTM level YoY 3-year change
ALNYAlnylam Pharmaceuticals, Inc.LTM Jun 202616.6% +32.1 pp+117.3 pp
IONSIonis Pharmaceuticals, Inc.LTM Sep 2026-56.7% -29.9 pp+3.7 pp
ARWRArrowhead Pharmaceuticals, Inc.LTM Sep 2026-160.6% -166.8 pp-74.8 pp
ARCTArcturus Therapeutics Holdings Inc.LTM Mar 2026-173.5% -122.7 pp-103.0 pp
WVEWave Life Sciences Ltd.LTM Mar 2026-255.7% -148.7 pp+3937.7 pp
PRQRProQR Therapeutics N.V.LTM Mar 2026-339.3% -179.1 pp+1518.7 pp
SLNSilence Therapeutics plcLTM Mar 2026-9241.5% —-15620.7 pp
Peer median (excluding ARWR) -214.6%-122.7 pp+60.5 pp

Competitors are the stored peer set for ARWR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2022
Sep 2022
FY2023
Sep 2023
FY2024
Sep 2024
FY2025
Sep 2025
FY2026
Sep 2026
Revenue243.23M240.74M3.55M829.45M450.82M
Cost of Revenue10.42M12.49M18.6M01.8M
Gross Profit232.81M228.24M(15.04M)829.45M449.02M
Gross Margin95.7%94.8%-423.7%100.0%99.6%
Research & Development288.5M342.31M489.22M607.16M739.14M
Selling, General & Admin124.43M90.93M96.82M121.92M202.05M
Operating Expenses411.32M433.24M586.04M731.1M1.16B
Depreciation & Amortization10.42M12.49M18.6M23.93M26.62M
EBITDA(162.29M)(175.67M)(561.51M)164.82M(603.59M)
EBITDA Margin-66.7%-73.0%-15812.8%19.9%-133.9%
Operating Income(178.51M)(205M)(601.08M)98.35M(707.17M)
Operating Margin-73.4%-85.2%-16927.1%11.9%-156.9%
Interest Income5.03M15.3M22.72M37.29M57.86M
Interest Expense018.33M32.35M89.36M93.71M
Other Income / Expenses5.8M(1.49M)(11.38M)(46.81M)(16.74M)
Income Before Tax(172.71M)(206.49M)(612.46M)51.53M(723.92M)
Pre-Tax Margin-71.0%-85.8%-17247.5%6.2%-160.6%
Income Tax Expense3.79M2.78M(2.77M)21.42M(6.78M)
Net Income(176.06M)(205.28M)(599.49M)(1.63M)(724.21M)
Net Margin-72.4%-85.3%-16882.4%-0.2%-160.6%
EPS (Basic)(1.67)(1.92)(5.00)(0.01)(5.11)
EPS (Diluted)(1.67)(1.92)(5.00)(0.01)(5.11)
Weighted Avg Shares105.43M106.75M119.78M133.76M141.63M
Weighted Avg Shares (Diluted)105.43M106.75M119.78M133.76M141.63M

Arrowhead Pharmaceuticals, Inc.

NASDAQ:ARWR

Intrinsic Alpha fair value

Locked

Current Price

$43.11

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.